The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.

You can also contact the CTN coordinating centre for additional information: (link sends e-mail)

Study Name on (link is external)
Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients
Study DrugMP-376 (Levofloxacin Solution for Inhalation)
Type of Study DrugAnti-infective
Study TitlePhase 3, Open-label, Randomized Trial to Evaluate the Safety and Efficacy of MP-376 Inhalation Solution (Aeroquin) vs. Tobramycin Inhalation Solution (TIS) in Stable CF Patients.
Study Phase3
Study SponsorMpex Pharmaceuticals

Link on (link is external) (link is external)

Participating ECFS-CTN sitesGermany: Berlin, Frankfurt, Munich
France: Montpellier, Bordeaux/Toulouse, West-Paris
UK: Belfast, Birmingham, Leeds, Nottingham
Age12 years and older